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ABSTRACT 
The paired-like homeobox 2B gene (PHOX2B) encodes a key transcription factor that plays 
a role in the development of the autonomic nervous system and the neural structures involved in 
controlling breathing. In humans, PHOX2B over-expression plays a role in the pathogenesis of 
tumours arising from the sympathetic nervous system such as neuroblastomas, and heterozygous 
PHOX2B mutations cause Congenital Central Hypoventilation Syndrome (CCHS), a life-
threatening neurocristopathy characterised by the defective autonomic control of breathing and 
involving altered CO2/H
+
 chemosensitivity. The recovery of CO2/H
+
 chemosensitivity and 
increased ventilation have been observed in two CCHS patients using the potent contraceptive 
progestin desogestrel. Given the central role of PHOX2B in the pathogenesis of CCHS, and the 
progesterone-mediated effects observed in the disease, we generated progesterone-responsive 
neuroblastoma cells, and evaluated the effects of 3-Ketodesogestrel (3-KDG), the biologically 
active metabolite of desogestrel, on the expression of PHOX2B and its target genes. Our findings 
demonstrate that, through progesterone nuclear receptor PR-B, 3-KDG down-regulates PHOX2B 
gene expression, by a post-transcriptional mechanism, and its target genes and open up the 
possibility that this mechanism may contribute to the positive effects observed in some CCHS 
patients. 
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INTRODUCTION 
Heterozygous mutations (frameshift mutations and poly-alanine triplet expansions) in the 
PHOX2B gene, a key transcription factor that plays a role in the development of the autonomic 
nervous system and the neural structures involved in controlling breathing [1,2], cause Congenital 
Central Hypoventilation Syndrome (CCHS; MIM# 209880), a syndrome of autonomic dysfunction 
that is characterised by life-threatening sleep-related hypoventilation caused by an abnormal 
ventilatory response to carbon dioxide: children affected by CCHS require ventilatory support 
during non-REM sleep (tracheostomy or non-invasive ventilation), although a milder degree of 
hypoventilation may also be present during REM sleep and wakefulness [3-5]. CCHS may also be 
associated with a spectrum of non-respiratory symptoms and other conditions (cardiac arrhythmias, 
ocular and endocrinological disorders) that reflect more generalised autonomic nervous system 
(ANS) dysregulation, including Hirschsprung’s disease and tumours of neural crest origin, and we 
and others have reported that the complexity of clinical phenotypes is influenced by the type of 
mutation (frameshift mutations vs poly-alanine triplet expansions), the type of translational frame, 
and gene dosage [6-13]. No pharmacological treatment has yet proved to be effective in improving 
the disease-related respiratory defects. Recent findings [14] have shown that two CCHS female 
patients (respectively with +5 and +6 alanine expansions) using the progestin contraceptive 
desogestrel for contraceptive purposes experienced a partial recovery of chemosensitivity and 
increased ventilation, thus opening up new prospects for a pharmacological intervention that could 
at least improve respiratory symptoms. Desogestrel has much greater affinity for progesterone 
receptors than progesterone itself [14,15]. 
Progesterone is a steroid that is primarily synthesised in the gonads, adrenal glands and 
placenta but, as it is also synthesised de novo in the central and peripheral nervous system, can be 
classified as a neurosteroid. It is well known that progesterone is a powerful respiratory stimulant 
that may be useful for treating adult apnea, and it has been suggested that it could also be used for 
the treatment of apnea in pre-term neonates [16-18]. Progesterone exerts its biological effects by 
binding nuclear or membrane progesterone receptors, and recent data provide evidence that nuclear 
receptors are important modulators of respiratory control during sleep and chemoreflex sensitivity: 
adult female mice from which the nuclear receptor has been deleted show more frequent sighs and 
post-sigh apnea during non-REM sleep, and reduced responses to hypercapnia after chronic 
progesterone treatment [19]. Although the exact molecular mechanism of the pharmacological 
effect of desogestrel is unknown, recent evidence indicates that multiple pathways, involving both 
medullary and supramedullary neurons, may play a role in the ventilatory effects of desogestrel 
[15,20]. It is also worth noting that a number of rodent brain structures (including some expressing 
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Phox2b in adulthood) are activated by desogestrel and the same structures may be involved in the 
recovery observed in the two CCHS patients; however, the contribution of PHOX2B and its 
mutations to respiratory improvement has not yet been investigated. 
Given the central role of the PHOX2B gene in the pathogenesis of CCHS and the co-
expression of progesterone receptors and PHOX2B in neurons that play a role in CO2 
chemosensitivity [21,22], the aim of this study was to determine whether treating PHOX2B-
expressing cell lines with the biologically active metabolite of desogestrel, 3-Ketodesogestrel (3-
KDG) or etonogestrel [23], affects the expression of PHOX2B and its target genes. In order to 
investigate the relationship between progestin and PHOX2B activity further, we generated a stable 
progestin-responsive SK-N-BE(2)C neuroblastoma cell line. Neuroblastoma is a universally 
accepted model of neural crest derivative, with most of the molecular features of a sympathetic 
ganglionic cell, a kind of structure heavily affected in Phox2b knock-out mice, that likely share a 
fraction of its PHOX2B-dependent transcriptome with other types of PHOX2B
+
 neurons. In this 
model, our results provide the evidence of a direct molecular link between PHOX2B and 
Desogestrel. 
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MATERIALS AND METHODS 
Cell cultures 
The SK-N-BE(2)C, IMR32 and SH-SYSY human neuroblastoma cell lines, and the MCF7 
and T47D breast carcinoma cell lines were grown in RPMI 1640, 100 units/mL penicillin, 100 
mg/mL streptomycin, 2 mM L-glutamine (LONZA), supplemented with 10% foetal bovine serum 
(FBS, Euroclone) at 37°C with 5% CO2. The T47D cell line was maintained in a medium with 
added human Insulin (Sigma) to a final concentration of 5μg/mL. 
To generate SK-N-BE(2)C neuroblastoma cell line stably expressing human progesterone 
receptors (PGRs), 7.5 x 10
5
 cells were plated in 100 mm dishes and transfected with 10 μg PGR-
pCDNA 3.1 myc-His plasmid using a FuGene HD (Promega) transfection reagent in a ratio of 1:4 
(DNA:FuGene). Forty-eight hours after transfection, the SK-N-BE(2)C cells were diluted 1:10 in 
100 mm dishes and grown under 700 μg/mL geneticin selection (G-418 Sulfate, Gibco), and the 
individual colonies were transferred to multi-well plates for further propagation. The selected 
clones were screened for the expression of intracellular progesterone receptor protein by means of a 
Western blot assay. The stable SK-N-BE(2)C 5.8 and 6.30 clones were maintained under selection 
by adding geneticin (G-418 Sulfate, Gibco) at a final concentration of 0.4 mg/mL, with selective 
medium changes every second day. The desogestrel treatments were carried out by adding 1 nM of 
the active 3- Keto-desogestrel metabolite (3-KDG, USBiological) for the times indicated in the 
figure legends. Transcript and protein stability were respectively measured by means of treatment 
with 75 μM 5,6 dichloro-beta-D-ribofuranosylbenzimidazole (DRB, Sigma) and 1 μg/mL 
Cycloheximide (CHX, Sigma) for the times indicated in the figure legend. 
 
Total RNA extraction, reverse transcription and qPCR 
To measure PHOX2B and PGR-B mRNA expression level, total RNA was extracted using 
the RNeasy™ Mini kit or RNA plus Micro kit and accompanying QIAshredder ™ (Qiagen, Hilden, 
Germany) in accordance with the manufacturer’s instructions. Five hundred nanograms of RNA 
were reverse transcribed using the GoScript
TM
 Reverse Transcriptase kit (Promega), and PHOX2B, 
PGR-B and GAPDH transcripts were quantitatively analysed using an ABI Prism Thermocycler 
QuantStudio 5 (Applied Biosystems, CA). The TaqMan® primer and probe assays (Life 
Technologies, Inc.) were human PHOX2B (ID #Hs00243679_m1), human PGR (ID 
#Hs01556702_m1), and the endogenous control GADPH (ID #Hs99999905_m1). Each sample was 
run in triplicate, and the results were calculated using the 2
−ΔCT
 and the 2
−ΔΔCT
 methods in order to 
allow the normalisation of each sample to GAPDH and comparisons with the calibrator of each 
experiment (set to a value of 1) as indicated in the figure legends. 
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Transient transfections and Luciferase assays 
To evaluate the TLX2-luc or DBH-luc reporter vectors activity, the cells were transiently 
transfected or co-transfected by means of lipofection using FuGENE HD transfection reagent 
(Promega) as previously described [24] using 1.7 x 10
5
 SK-N-BE(2)C cells. Twenty-four hours 
after transfection, the cells were treated with 1 nM of 3-KDG (USBiological) or 3 nM progesterone 
(Sigma) for the times indicated in the figure legends. 
Luciferase was assayed using the Dual Luciferase Reporter Assay System (Promega) in a 
GloMax Discovery Luminometer (Promega), and the results were analysed as previously described 
[24]. All of the transfections were performed in triplicate, and each construct was tested in at least 
three independent experiments using different batches of plasmid preparation. The results are given 
as mean values ± standard deviation (SD), and the data were analysed using an unpaired two-tailed 
Student's t test or one-way ANOVA and GraphPadPrism 5 Software (GraphPad Software, Inc.) as 
described in the figure legends; p values of <0.05 were considered significant. 
 
Plasmid construction 
The hPGR-pCDNA 3.1 myc-His plasmid, containing the human intracellular progesterone 
receptor and used to generate the stable SK-N-BE(2)C clones, was obtained by re-cloning the 
region corresponding to the human PR-A encoding sequence (kindly gifted by Angelo Poletti, 
University of Milan) into the Bam HI sites of the pCDNA 3.1 myc-His vector (InVitrogen). The 
region encoding the N-terminus of the PR-B isoform was amplified by means of PCR using cDNA 
extracted from T47D cells and the GC-rich PCR system (Roche Applied Science), and sub-cloned 
into the Kpn I and BstE II sites of the pCRII vector (InVitrogen). The oligonucleotide sequences 
were: forward primer, 5’-CGT CAG ACT GAG CTG AAG GCA AAG- 3’; and reverse primer, 5’ -
GGT GGA TCT TCG GGA AGT TCG GG- 3’. In order to obtain the full-length hPGR-pCDNA 
3.1 myc-His construct, the 5’PR-B fragment was cloned upstream of the hPR-A fragment in the 
hPR-A-pCDNA 3.1 myc-His plasmid, after double enzymatic digestion with Kpn I/Pf1M I 
restriction enzymes. 
The TLX2 (-1185bp) and DBH promoter constructs, used to evaluate the effect of 
desogestrel on the transcription activity of PHOX2B target genes, have been previously described 
[25,26]. The progesterone responsive MMTV promoter reporter construct contained the murine 
mammary tumour virus long terminal repeat (MMTV LTR) inside the pGL3-basic vector 
(Promega).  
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All of the constructs were checked by means of restriction analysis and partial sequencing of 
both strands. All of the enzymes used for the cloning were purchased from New England Biolabs. 
 
Protein preparation and Western Blot analyses 
 For evaluating the effect of desogestrel on PHOX2B and its target genes protein level, total 
protein extract was prepared from SK-N-BE(2)C cells and the 5.8 and 6.30 clones stably over-
expressing PGR using the freeze and thaw method, and was analysed by means of Western blotting 
as previously described [27]. Table S1 shows the primary and secondary antibodies used. 
After appropriate washes, the bands were revealed using Super Signal West Dura (Thermo Fisher 
Scientific), for the secondary antibodies conjugated with horseradish peroxidase, or the Odyssey 
CLx Infrared Imaging System for infrared-conjugated IgG IRDye (LI-COR Bioscience). A standard 
molecular weight (PageRuler
TM
 Broad Range Unstained Protein Ladder, Thermo-Fisher Scientific 
and Prestained Protein SHARPMASST
M
 VII, EuroClone) was loaded in parallel. Densitometric 
analysis of the obtained signals was carried out using NIH ImageJ 1.61/fat, or Image Studio (LI-
COR Biosciences) software, and the results are shown as the mean values ± standard deviation (SD) 
of at least three independent experiments.  
The statistical analyses were made using ANOVA or an unpaired two-tailed Student’s t test 
and GraphPad Prism 5 Software (GraphPad Software, Inc.) as indicated in the figure legends. P 
values of < 0.05 were considered significant.  
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RESULTS  
Identification of a cell model to study the effect of 3-KDG on PHOX2B 
In order to investigate the mechanism of action of the desogestrel and whether it can affect 
the expression or activity of PHOX2B and some relevant PHOX2B target genes, we carried out 
preliminary experiments using the T47D human breast adenocarcinoma cell line, because it has the 
advantage of expressing intracellular and membrane-associated progesterone receptors, but lacks 
PHOX2B expression. The preliminary experimental evidence obtained by co-transfecting PHOX2B 
cDNA and the TLX2-luc PHOX2B target gene promoter into the T47D cells showed that 3-KDG 
(the active metabolite of desogestrel) up-regulates the transcription of the TLX2 promoter reporter 
vector, an effect that is mainly mediated by the intracellular progesterone receptor PR-B (data not 
shown). 
This interesting finding and the notion that neurons that play a central role in CO2 
chemosensitivity co-express progesterone receptors and PHOX2B [21,22] prompted us to study the 
effect of desogestrel on the PHOX2B pathway in a cell model whose cellular background is more 
closely associated with the physiological PHOX2B environment also in terms of co-activators and 
co-repressors. To this end, we used real-time PCR to characterise PHOX2B expression (Fig. S1A, 
grey bars) and progesterone receptor (PGR, the main receptor mediating 3-KDG activities; see Fig. 
S1A, black bars) in various neuroblastoma cell lines. The IMR32, SK-N-BE(2)C and SH-SY5Y cell 
lines showed PHOX2B expression, but only IMR32 and SK-NBE(2)C also expressed PGR, albeit at 
a level that was 30,000 and 200,000 times lower than its expression in the T47D cell line (Fig. S1A, 
black bar). Despite their PGR expression, these cell lines were not responsive to progesterone or 3-
KDG treatment, as confirmed by transient transfection with the PGR-responsive reporter construct 
MMTV-luc (Fig. S1B, left bars), due to the absence of the PGR protein (Fig. 1A, lanes 1 and 2), but 
they could be made responsive by transiently co-transfecting the PGR expression vector (Fig. S1B, 
white striped and cross-hatched bars vs white empty bar). One possibility of the observed loss of 
progesterone receptor is that neuroblastoma cells express alternatively spliced PGR mRNA variants 
that give rise to PGR that miss functional domains and make them undetectable by the antibodies 
used in this study, as already described [28]. Consequently, although the IMR32 cell line expressed 
higher basal PHOX2B and PGR transcript levels than SK-N-BE(2)C (Fig. S1A), we decided to use 
SK-N-BE(2)C because of its greater capacity for transfection. 
 
3-KDG reduces the expression of PHOX2B and of its target genes  
Western blot and densitometric analyses of SK-N-BE(2)C cells transiently transfected with 
PGR cDNA (hPGR-pcDNA3.1 myc-His) (Fig. 1A, lanes 3 and 4) or pCDNA3 control vector (Fig. 
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1A, lanes 1 and 2) and treated with 1 nM of 3-KDG for 48 hours (Fig. 1A, lanes 2 and 4) showed 
that PHOX2B protein levels were significantly reduced 3-fold in the cells transfected with hPGR 
and treated with 3-KDG in comparison with untreated cells (Fig. 1B, white striped bar vs white 
bar), whereas no significant effect was observed in the cells transfected with the control vector (Fig. 
1B, striped vs plain black bars), thus confirming that 3-KDG has a direct effect on the expression of 
PHOX2B protein in this cell line. Similarly, the PHOX2B mutant protein carrying one of the most 
frequent poly-alanine expansion (+7) observed in CCHS was down-regulated upon treatment with 
3-KDG (data not shown). 
The down-regulation of PHOX2B protein expression after 3-KDG treatment affects the 
promoter activity of two known PHOX2B target genes, T-cell leukaemia homeobox 2 (TLX2), and 
dopamine beta-hydroxylase (DBH), both expressed in the SK-N-BE(2)C cell line. Figures 1C and 
1D respectively show a significant 8- and 5-fold decrease in luciferase activity in the cells co-
transfected with hPGR and the TLX2-luc or DBH-luc reporter vectors and treated with 3-KDG 
(white striped bars vs white empty bars). Progesterone had a slightly less efficient but still 
significant effect (Fig. 1C and 1D, white cross-hatched bars vs white empty bars), as it led to a 4-
fold and 2-fold reduction in TLX2 and DBH promoter activity. The control cells transfected with 
luciferase promoter-less reporter constructs pGL3b (vs TLX2-luc) and pGL4b (vs DBH-luc) did not 
show any significant reduction induced by progestin treatment (Fig. 1C and 1D, striped and cross-
hatched vs empty grey bars), thus confirming the consistency of the effect of 3-KDG on the two 
PHOX2B target genes, and suggesting that this reduction may be due to decreased PHOX2B 
protein availability. 
 
3-KDG down-regulates endogenous PHOX2B protein and target genes in stable progestin-
responsive SK-N-BE(2)C cells 
In order to investigate the relationship between progestin and PHOX2B activity further, we 
generated a stable progestin-responsive SK-N-BE(2)C neuroblastoma cell line that allowed us to 
avoid the limiting step of the transient PGR transfection (Fig. S2A). The PGR expressing vector 
used for the stable transfection encodes the two isoforms of intracellular progesterone receptors: the 
full-length B isoform (PR-B) and the N-terminal truncated isoform (PR-A). Two clones, that had 
different relative expression levels of the PR-A and PR-B isoforms and named 5.8 and 6.30, were 
chosen for further analyses (Fig.S2A). 
Figure 1A showed that 3-KDG treatment reduced PHOX2B protein levels in SK-N-BE(2)C 
cells transiently transfected with PGR. In order to investigate the mechanism underlying this 
reduction further and analyse the possible effect of 3-KDG on the PHOX2B pathway, the stable 
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SK-N-BE(2)C clones 5.8 and 6.30 were treated with 1 nM 3-KDG for 8, 24 and 48 hours, and the 
endogenous level of PHOX2B and of some known PHOX2B target genes was evaluated (Fig. 2 and 
Fig.3). Western blotting (Fig. 2A) and quantification analyses (Fig. 2B) showed that treatment 
significantly reduced the level of PHOX2B protein in both clones (Fig 2B, grey and white striped 
bars vs grey and white empty bars) in comparison with the native SK-N-BE(2)C cells used as 
controls (Fig 2B, black striped and empty bars), albeit with different kinetics between clones. 
PHOX2B protein level decreased more rapidly in clone 5.8 than in clone 6.30 (Fig 2A, lanes 6-8 vs 
lanes 10-12), as it was 35% in clone 5.8 and 90% in clone 6.30 after eight hours treatment (Fig. 2B, 
grey vs white striped bars). 
We then investigated whether a reduced PHOX2B protein level could affect the expression 
of some of its already known target genes, DBH and TFAP2A (Ap2α). As shown in Figure 3A, as in 
the case of PHOX2B, a significant reduction in proteins level at each time point was observed in 
clone 5.8 (Fig. 3A, lanes 6-8 vs lane 5), in comparison with the treated native cells (Fig. 3A, lanes 
2-4 vs lane 1). In particular, after 48 hours 3-KDG treatment DBH was almost undetectable (Fig. 
3B, grey striped bar), whereas TFAP2A was reduced by 95 % only after eight hours (Fig. 3C, grey 
bars). DBH and AP2α levels were also reduced in clone 6.30 (Fig. 3B and C, white bars), but to a 
lesser extent, which led us to hypothesise that the amount of PR-B may affect the expression of 
these genes differently. 
For control purposes, we analysed the expression of proteins that are not direct PHOX2B 
target genes, such as SP1, CREB and c-JUN (Fig. S3A). There was no significant change in their 
expression in either of the clones (Fig. S3B to D) or in the control cells, thus confirming the direct 
effect of desogestrel on PHOX2B expression and/or activity.  
In conclusion, our findings demonstrated that 3-KDG directly affects PHOX2B and its target 
genes by reducing their expression, thus indicating that it has a specific effect on the PHOX2B 
pathway. 
 
3-KDG partially affects PHOX2B mRNA degradation 
In order to investigate the mechanism underlying these effects further, we tested whether the 
decrease in protein level in clone 5.8 (which showed the most rapid kinetic reduction in PHOX2B 
protein) was due to reduced transcription or a post-transcriptional level mechanism. 
Quantitative PCR analysis of PHOX2B mRNA expression level (Fig. 4A) in SK-N-BE(2)C clone 
5.8 and native SK-N-BE(2)C cells treated with 1 nM 3-KDG for eight, 24 and 48 hours showed that 
3-KDG significantly reduced PHOX2B mRNA level by 50%, (Fig. 4A grey bars) and, unlike the 
protein, which showed a significant reduction of up to 10% (Fig. 2A), this was maintained during 
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the following 48 hours of treatment. No change in the level of mRNA was observed in the native 
SK-N-BE(2)C cells (Fig 4A, black bars). As shown in Figure 4B (grey bars), PHOX2B mRNA 
levels were reduced after as little as two hours of treatment, thus supporting the hypothesis that the 
reduction in PHOX2B protein was partially due to a reduction in mRNA, which may occur because 
of reduced transcription or reduced transcript stability. 
In order to clarify this, we measured the stability of PHOX2B mRNA in clone 5.8, by 
determining its decay after using the RNA pol II inhibitor DRB to inhibit transcription in the 
presence and absence of 3-KDG treatment (Fig. 4C). Before adding DRB, the cells were pre-treated 
for 24 hours with 3-KDG or vehicle alone (Fig. 4C). The level of PHOX2B mRNA was reduced by 
50% in approximately one hour regardless of the presence (Fig. 4C, solid line) or absence of 3-
KDG (Fig. 4C dashed line) but, after two hours, it became significantly different because the 
mRNA was no longer degraded in the absence of 3-KDG (Fig. 4C). This was not due to the 
induction of transcription of the factor required to degrade PHOX2B mRNA by 3-KDG because the 
same result was obtained when 3-KDG was added to DRB (Fig. 4D). 
These findings suggest that 3-KDG partially affects PHOX2B mRNA stability, and indicate 
that the 50% reduction in mRNA was due to greater degradation in the treated sample. 
 
3-KDG does not affect PHOX2B protein stability 
The reduction in PHOX2B mRNA levels in experiments in Figures 4A and 4B does not 
totally explain the drastic reduction in protein levels in clone 5.8 after 3-KDG treatment (Fig. 2A). 
In order to investigate the underlying mechanism further, we tested whether 3-KDG also affects 
PHOX2B protein stability by pre-treating SK-N-BE(2)C clone 5.8 cells with 1µg/mL 
cycloheximide (CHX) for one hour, followed by the addition of 3-KDG or DMSO for different 
times (Fig. 5A), and found no difference in the PHOX2B degradation rate (Fig. 5B, dashed line vs 
solid line). Pre-treatment with 3-KDG before adding CHX confirmed that 3-KDG does not induce a 
factor acting on the degradation of PHOX2B protein.  
In conclusion, our findings demonstrated that the effects of 3-KDG on PHOX2B are 
mediated by increased PHOX2B mRNA degradation (Figs. 4C and D). As the drastic reduction in 
PHOX2B protein cannot be exclusively attributed to increased protein degradation, we hypothesise 
that 3-KDG reduces PHOX2B protein by also blocking its translation. 
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DISCUSSION 
The findings of this study demonstrate that the biologically active metabolite of desogestrel, 
3-KDG, modulates PHOX2B gene expression via progesterone nuclear receptor PR-B. Treatment 
with 3-KDG decreased both PHOX2B mRNA and protein levels as a result of an increased mRNA 
degradation rate and possibly concomitant translation inhibition. Apparently, the increase in mRNA 
degradation rate and inhibition of translation do not require the synthesis of new molecules, and so 
the molecular factor(s) involved in the two processes remain to be identified and further 
investigated. Moreover, PHOX2B protein down-regulation is paralleled by a decrease in two of its 
well known target genes (DBH and TFAP2A), whereas other genes not regulated by PHOX2B are 
not affected.  
Transcription block experiments showed that the kinetics of PHOX2B mRNA degradation is 
biphasic: almost one half is rapidly degraded in one hour but, after that, the degradation slows and 
there is no further decrease in mRNA level, thus suggesting the existence of two PHOX2B mRNA 
pools. Our findings indicate that 3-KDG increases the rate of PHOX2B mRNA degradation, and in 
particular that of the more stable pool of mRNAs. Given that the PHOX2B 3’ untranslated region 
(3’UTR), and the microRNAs (miRNAs) targeting it are important for the post-transcriptional 
regulation of the PHOX2B gene, a possibility is that various isoforms of different 3′ UTR lengths 
are synthesised and have distinct properties and different degradation rates [29]. However, mRNA 
does not completely disappear and is maintained at a certain level by means of compensatory 
transcriptional up-regulation. As we observed very little induction of the PHOX2B promoter 
reporter construct (data not shown), we cannot exclude the possibility that the degradation induces a 
more general synthesis [30]. The different steady-state levels of PHOX2B protein at different time 
points of treatment and in two stable clones differently expressing progesterone receptors influence 
the degree of down-regulation of PHOX2B target genes in a gene specific manner. A slight 
decrease in PHOX2B is not sufficient to down-regulate all PHOX2B target genes, and it has been 
previously reported that the partial silencing of PHOX2B only slightly affects PHOX2B target gene 
expression [31]. Interestingly, progesterone induces the up-regulation of tyrosine hydroxylase, a 
well-known PHOX2B target gene, in the SK-N-SH neuroblastoma cell line (which is negative for 
PHOX2B and expresses very low levels of PHOX2A) and in the noradrenergic CAD cell line 
(which expresses higher levels of PHOX2A than PHOX2B), thus suggesting that PHOX2B  and the 
cellular context play a critical role in determining positive or negative progesterone-mediated 
effects [32].  
Unlike what has been observed in neuroblastoma cell lines in which PHOX2B over-
expression plays a pathogenic role, the respiratory and autonomic symptoms of CCHS patients, and 
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their predisposition to Hirschsprung’s disease and intestinal developmental and functional defects, 
are due to PHOX2B haploinsufficiency [12,33]. In this perspective, the positive effects of 
desogestrel on ventilation and chemosensitivity observed in two CCHS patients [14,15] are 
somewhat unexpected because, at molecular level, 3-KDG decreases PHOX2B expression. 
However, in vivo findings argue against the idea that CCHS is due to a pure loss-of-function 
mechanism, and it is likely that toxic functions gained by mutant proteins also contribute to the 
respiratory defects [34-39]. In this light, as we observed that PHOX2B mutant protein levels 
decrease similarly to those of its wild-type counterpart after 3-KDG treatment (data not shown), the 
beneficial effect of decreasing the level of the mutant PHOX2B may clinically compensate for the 
potential pathogenic effect of insufficient PHOX2B expression, especially after birth when the 
differentiation of a number of PHOX2B
+
 cell types and autonomic nervous system components 
such as the enteric nervous system (ENS) has already occurred, at least in patients carrying mild 
PHOX2B polyAla expansions. It is worth noting that the role of Phox2b and its mutations has been 
widely investigated during embryonic development, but their exact role in adulthood is still unclear. 
Phox2b gene expression persists in various structures in adult rats and human [21,40], and various 
findings indicate that it plays a role in maintaining the function of noradrenergic neurons in the 
adult [41]. Recent studies have also shown residual cardiorespiratory responses in prevalently 
younger CCHS patients, thus suggesting age-dependent mechanisms such as the developmental 
reconfiguration of respiratory circuits or the continuing loss of vulnerable cell populations within 
them due to the expression of an altered PHOX2B transcription factor [42]. In mouse models of 
CCHS, the development of the retrotrapezoid nucleus (RTN), which expresses Phox2b, is 
particularly vulnerable to different Phox2b mutations (frameshift mutations and poly-alanine triplet 
expansions) that cause CCHS in humans [34,38,39], and dysfunctioning CO2/H
+
 
chemosensitive/Phox2b-positive neurons in the RTN/pFRG is generally thought to play a critical 
role in perinatal respiratory control in rodents [43]. However, the fact that mice can survive the 
selective genetic deletion of the RTN PHOX2B-positive neurons and the loss of breathing 
stimulation by CO2 suggests that the neurological basis of CCHS is not confined to the absence of 
the RTN and that compensatory mechanisms may partially restore CO2 sensitivity [36]. Other 
structures, including some expressing Phox2b in adulthood, are grossly unaltered in Phox2b mutant 
mice (and reasonably in humans), and may be involved in the recovery of the two CCHS patients. 
One putative structure is the nucleus of the solitary tract (NTS), which expresses Phox2b in adult 
rats, is not affected by Phox2b poly-alanine mutations, and contains neurons that are inhibited by 
hypoxia but whose activity is restored by progesterone administration [34,44-46]. Consistently, 
neurons in the commissural part of the NTS are activated by 3-KDG [15,20]. C1 neurons may also 
14 
 
be involved in the recovery of the two CCHS patients as PHOX2B has been identified in selected 
populations of TH-expressing neurons in adult rats, including the C1 neurons [44] that regulate the 
breathing network at multiple levels [47,48]. It has also been shown that 3-KDG activates 
catecholaminergic neurons in the ventrolateral medullary reticular nucleus [15].  
In conclusion, although our results are based on an in vitro system such as neuroblastoma 
cell lines, the findings of this study provide the evidence of a direct molecular link between 
PHOX2B and Desogestrel by showing that 3-KDG down-regulates the expression of PHOX2B and 
its target genes and open up the possibility that the down-regulation of PHOX2B and mutant 
proteins may contribute to the recovered chemosensitivity and increased ventilation observed in the 
two CCHS patients taking desogestrel. However, further research is needed to evaluate the 
usefulness of pharmacological approaches targeting PHOX2B and possibly attenuating the 
deleterious effects of PHOX2B mutations in CCHS patients.  
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FIGURE LEGENDS 
Figure 1. Effects of 3-KDG on the expression of PHOX2B protein and its transcriptional 
activity on the TLX2 and DBH target promoters  
A and B) Western blot analysis and quantification of the effect of 3-KDG on PHOX2B endogenous 
protein in SK-N-BE(2)C cells. A) Total protein extracts of SK-N-BE(2)C cells transfected with the 
PGR expression vector (lanes 3 and 4) or the empty vector pCDNA3 (lanes 1 and 2), and treated 
with 3-KDG for 48 hours (lanes 2 and 4). Extracts of the IMR32 (lane 5) and T47D cell lines (lane 
6) were respectively used as positive controls of PHOX2B and PGR expression. B) Relative 
quantification of PHOX2B protein in untreated (black and white bars) and 3-KDG treated cells 
(hatched bars). The results are the mean PHOX2B values (± SD, error bars) normalised to that of β-
tubulin (TUB) in two independent experiments, and are expressed as fold-induction over untreated 
cells (=1). *p<0.05, significant differences in PHOX2B levels between the treated (white hatched 
bar) and untreated (white bar) cells transfected with the hPGR vector (Student’s t test). C and D) 
Luciferase assay. The bars indicate the transcriptional activity of reporter constructs driven by the 
TLX2 (C, right) and DBH promoter (D, right) upon the co-transfection of the PGR expression vector 
in SK-N-BE(2)C cells treated with 1 nM 3-KDG (hatched bars) or 3 nM progesterone (cross-
hatched bars) for 48 hours. The empty vectors pGL3b (C, left) and pGL4b (D, left) were used as 
negative controls (grey bars). The results are the mean values ± SD (error bars) of the 
transcriptional activity of the constructs in at least five experiments performed in duplicate, and are 
expressed as RLU normalised to that of Renilla. ***p<0.001, significant differences in activity 
between the treated and untreated cells transfected with TLX2 or DBH promoters (one-way 
ANOVA, Tukey’s test). 
Figure 2. Effects of 3-KDG on endogenous PHOX2B protein in stable SK-N-BE(2)C hPGR 
clones. 
A) Representative Western blot of endogenous PHOX2B in SK-N-BE(2)C cells stably over-
expressing hPGR (clones 5.8 and 6.30, lanes 5 to 12) and untransfected SK-N-BE(2)C cells (lanes 1 
to 4) after treatment with 1 nM 3-KDG for eight, 24 or 48 hours. IMR32 nuclear extract (IMR32 
NE, lane 13) and T47D (lane 14) were respectively used as positive and negative controls for 
PHOX2B. B) The bar chart shows the relative quantification of PHOX2B protein in native SK-N-
BE(2)C cells (black bars), SK-N-BE(2)C clone 5.8 cells (grey bars) and SK-N-BE(2)C clone 6.30 
cells (white bars) after 3-KDG treatment (hatched bars). The data show the relative fold induction in 
the treated samples in relation to the untreated samples (=1), and are expressed as the mean values 
(± SD, error bars) of the densitometry intensity of each lane normalised to β-tubulin (TUB) in at 
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least three independent experiments. ***p <0.001, **p<0.01 and *p<0.05, significant differences in 
PHOX2B protein levels between treated and untreated (-) clones 5.8 and 6.30 (one-way ANOVA, 
Tukey's test). 
Figure 3. Effects of 3-KDG on PHOX2B target genes.  
A) Representative Western blots of PHOX2B target genes expression in stable SK-N-BE(2)C clones 
5.8 (lanes 5-8) and cl. 6.30 (lanes 9-12), and native SK-N-BE(2)C cells (lanes 1-4) after treatment 
with 1 nM 3-KDG for eight, 24 or 48 hours. The DBH and TFAP2A signal were normalised to that 
of β-tubulin (TUB). B, and C ) The bar charts show the relative quantification of DBH (B) and 
TFAP2A (AP-2 alpha, C) protein levels in native SK-N-BE(2)C cells (black bars), clone 5.8 (grey 
bars) and clone 6.30 cells (white bars) after 3-KDG treatment (hatched bars). The data indicate the 
relative fold induction in the treated samples in relation to the untreated samples (=1), and are 
expressed as the mean values ± SD (error bars) of at least three independent experiments. **p<0.01 
and *p<0.05, significant differences in DBH (B) and TFAP2A (C) protein levels between the 
treated and untreated (-) cells (one-way ANOVA, Tukey's test). 
 
Figure 4. 3-KDG affects PHOX2B mRNA stability 
A) Time course qPCR analysis of endogenous PHOX2B mRNA expression normalised to that of the 
GAPDH gene in native SK-N-BE(2)C (black bars) and clone 5.8 cells (grey bars) treated with 1 nM 
3-KDG (hatched bars) for the indicated times. The bars indicate the relative fold induction in the 
treated samples in relation to the untreated samples (=1) calculated using the 2
−ΔΔCT
 method, and are 
expressed as the mean values ± SD (error bars) of at least three independent experiments performed 
in triplicate. *p <0.05, statistically significant differences in PHOX2B mRNA expression in SK-N-
BE(2)C clone 5.8 cells, between the treated and untreated samples (one-way ANOVA, Tukey's 
test). B) The same experiment as in A was performed for a shorter time. The bars represent the mean 
values ± SD (error bars) of fold induction in comparison with the untreated sample (=1 grey bar) in 
a single representative experiment performed in triplicate. ***p<0.001, statistically significant 
differences between the treated and untreated samples (one-way ANOVA, Tukey's test). C and D) 
PHOX2B mRNA decay determined by qPCR analysis. C) Top: schematic representation of the 
protocol. SK-N-BE(2)C clone 5.8 cells were pre-treated with 1 nM 3-KDG (graph solid line), or 
vehicle (DMSO; graph dashed line) for 24 hours before the addition of 75 μM DRB for different 
times. D) Top: schematic representation of the protocol. SK-N-BE(2)C clone 5.8 cells were treated 
with 1 nM 3-KDG (solid line) or DMSO (dashed line) together with DRB (75 μM) for different 
times. Data are represented as mean values ± SD (error bars) of three (panel C) and two (panel D) 
independent experiments performed in triplicate, and normalised to the endogenous GAPDH gene. 
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PHOX2B mRNA levels at each time point were compared to those in untreated cells (initial level, 
T0=1 in panel C; or =1 in panel D), and are expressed as fold induction calculated using the 2
−ΔΔCT
 
method. Non-linear regression analysis was used to calculate one-phase exponential PHOX2B 
mRNA decay (GraphPad Prism 5.0). ***p<0.001, **p<0.01 and *p<0.05, statistically significant 
differences in PHOX2B mRNA levels between each time point and T0 (one-way ANOVA, Tukey's 
test). 
##
p<0.01 and 
#
p<0.05, statistically significant differences in PHOX2B mRNA levels between 
treated and untreated cells after two and four hours of DRB treatment (Student’s t test). 
Figure 5. 3-KDG does not affect PHOX2B protein stability 
A and C) Top: schematic representation of the protocol. Bottom: representative Western blots. A) 
SK-N-BE(2)C clone 5.8 cells were pre-treated with 1µg/mL CHX for one hour (lane 3) and the 
treatment was continued with (lanes 4-7) or without 1 nM 3-KDG (lanes 8-11) for the indicated 
times. Lane 2: untreated cells. IMR32 nuclear extract (IMR32 NE, lane 1) was used as a positive 
control for PHOX2B. The PHOX2B signal was normalised to that of β-tubulin (TUB). C) SK-N-
BE(2)C clone 5.8 cells were pre-treated with (lanes 2-7) or without (lanes 8-13) 1 nM 3-KDG for 
two hours before the addition of 1µg/mL CHX. IMR32 nuclear extract (IMR32 NE, lane 1) was 
used as a positive control for PHOX2B. B and D) Quantification. The graphs show the relative 
quantification of PHOX2B protein levels at each time point in comparison with T0 (=1): i.e. before 
the addition of DMSO/3-KDG (protocol A) or CHX (protocol C) in the treated (solid line) and 
untreated samples (dashed line) expressed as the mean densitometry intensity values ± SD (error 
bars) of each lane normalised to that of β-tubulin in two independent experiments. Non-linear 
regression analysis was used to calculate one-phase exponential decay (GraphPad Prism 5.0). 
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